Skip to main content
. 2020 Oct 7;8(2):e000726. doi: 10.1136/jitc-2020-000726

Figure 2.

Figure 2

Exposure to corticosteroid therapy (CT, panel A) and timing of CT (panels B, C) do not influence the overall survival and progression-free survival (panels D, E, F) of patients with hepatocellular carcinoma receiving immune checkpoint inhibitors.